Adding Merck's Keytruda To Chemo Halves Death Risk For Lung Cancer Patients

Back in November, Merck & Co. said its immuno-oncology star, Keytruda, had topped chemo at lengthening the lives of some esophageal cancer patients. Monday, it showed that the win was a sizable one.

Source :

Merck's Keytruda slashes death risk by 31% in esophageal cancer win
Merck Steals The Show At ASCO 2018 With Impressive Front-Line Lung Cancer Data
Merck's Keytruda shown to extend lung cancer survival in 2 trials
Merck wins early U.S. approval for Keytruda in untreated lung cancer
This New Drug Combination Doubles the Chance of Keeping Lung Cancer at Bay
Lung cancer: Merck drug shines
Many breast cancer patients can skip chemo, big study finds
'New day' in lung cancer as Merck drug shines, works with chemo
Merck’s Keytruda Cuts Death Risk by 31 Percent in Esophageal Cancer
Merck Obtains Earlier FDA Approval For Expanded Label Of Keytruda In Front-Line Lung Cancer